Rapalogix Health

Pioneering a new category of longevity-based skin health

New York, United States · Founded 2024 · $20.0M raised

Headquarters
New York
Employees
1–10
Founded
2024
Business Model
B2B
Total Funding
$20.0M
Last Round
$20.0M Series AJun 2026
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.

About

Rapalogix Health is a biotechnology company focused on translating longevity science into transformative dermatological therapeutics and skincare solutions. The company's scientific platform is built around TORC1 (a component of mTOR), one of the most extensively studied cellular pathways associated with aging. By selectively inhibiting TORC1, Rapalogix aims to address the underlying biology of skin aging and treat dermatological disorders including rosacea, acne, atopic dermatitis, and psoriasis. The company develops both prescription therapeutics—advancing RLX-202, a selective TORC1 inhibitor targeting chronic skin conditions with an IND planned for 2028—and the Re-Q Health professional skincare line powered by RLX-201, available exclusively through dermatology and aesthetic physician practices. Founded by skin longevity scientist Rahul Mehta PhD, dermatologist Doris Day MD, and healthcare executive Brent Saunders.

Summary

Rapalogix Health is a Biotech company based in New York, United States, founded in 2024. It has raised $20.0M in total across 1 round, most recently a $20.0M Series A round in Jun 2026. Investors include Quiet Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJun 2026
$20.0M

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Rapalogix Health on Indexed.vc
<a href="https://indexed.vc/companies/rapalogix-health"><img src="https://indexed.vc/api/badge/company/rapalogix-health" alt="Rapalogix Health on Indexed.vc" width="260" height="76" /></a>